# US 2026/0061026 A1 · Combination of inositol phosphorylceramide synthetase inhibitor and amphotericin b, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061026 A1
- Document ID: US20260061026A1
- Status: Published application
- Kind: A1
- Application number: 19/273,167
- Filed: 2025-07-18
- Published: 2026-03-05
- Earliest claimed: 2023-01-20
- Assignees: Institute of Microbiology, Chinese Academy of Sciences
- Applicants: Institute of Microbiology, Chinese Academy of Sciences
- Inventors: Linqi WANG; Leixin YE; Lei CHEN; Xiuyun TIAN; Lanyue ZHANG
- Web page: https://patentgrep.com/patent/US20260061026A1

## CPC

- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
an inositol phosphorylceramide synthase inhibitor; and
amphotericin B or a salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, provided as a unit-dose preparation, the pharmaceutical composition comprising:
an inositol phosphorylceramide synthase inhibitor; and
1 to 45 mg of amphotericin B or a salt thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, provided as a pharmaceutical combination or kit, the pharmaceutical composition comprising:
an inositol phosphorylceramide synthase inhibitor, as a first active ingredient; and
amphotericin B or a salt thereof, as a second active ingredient.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein:
the inositol phosphorylceramide synthase inhibitor comprises a cyclic depsipeptide antibiotic; or
the salt of amphotericin B, if present, comprises at least one of: sulfate, phosphate, citrate, tartrate, fumarate, benzoate, adipate, succinate, mesylate, deoxycholate, or maleate of amphotericin B;
optionally, a mass ratio of the inositol phosphorylceramide synthase inhibitor to amphotericin B or the salt thereof ranges from 1:3 to 5:1.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the cyclic depsipeptide antibiotic comprises at least one of aureobasidin A, enniatin, destruxin, emodepside, or fusafungine.

### Claim 6 (depends on 4)

The pharmaceutical composition according to claim 4, wherein:
the cyclic depsipeptide antibiotic comprises aureobasidin A;
optionally, the mass ratio of the inositol phosphorylceramide synthase inhibitor to amphotericin B or the salt thereof ranges from 1:2 to 4:1.

### Claim 7 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the mass ratio of the inositol phosphorylceramide synthase inhibitor to amphotericin B or the salt thereof is 1:2, 1:
1, 2:1, or 4:1.

### Claim 8 (depends on 4)

The pharmaceutical composition according to claim 4, further comprising a delivery carrier;
optionally, the delivery carrier comprises a liposome.

### Claim 9 (depends on 4)

The pharmaceutical composition according to claim 4, comprising:
an inositol phosphorylceramide synthase inhibitor, as a first active ingredient;
amphotericin B or a salt thereof, as a second active ingredient; and
at least one of 5-fluorocytosine or an azole antifungal compound, as a third active ingredient;
optionally, wherein the first active ingredient, the second active ingredient, and/or the third active ingredient are formulated collectively or separately;
optionally, wherein the first active ingredient, the second active ingredient, and/or the third active ingredient are encapsulated in one or more liposomes individually or collectively.

### Claim 10 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the liposome comprises a phospholipid.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the liposome further comprises a brain-targeting ligand; optionally, the brain-targeting ligand comprises glutathione.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the phospholipid comprises lecithin;
optionally, wherein the lecithin comprises at least one of soybean lecithin or egg yolk lecithin;
optionally, wherein a mass ratio of the phospholipid to the brain-targeting ligand ranges from 2:3 to 1:1.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the mass ratio of the phospholipid to the brain-targeting ligand is 5:6.

### Claim 14 (depends on 4)

The pharmaceutical composition according to claim 4, further comprising 5-fluorocytosine or an azole antifungal compound;
optionally, wherein the pharmaceutical composition is in a form of an injection preparation or an oral preparation.

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9, wherein:
the first active ingredient, the second active ingredient, and the third active ingredient are administered simultaneously or separately;
optionally, at least one of the first active ingredient, the second active ingredient, or the third active ingredient is in a form of an injection preparation or an oral preparation.

### Claim 16 (depends on 1)

A method for prolonging half-life of amphotericin B or a salt thereof or improving an inhibitory activity of amphotericin B or a salt thereof or an inositol phosphorylceramide synthetase inhibitor against Cryptococcus neoformans, comprising administering the pharmaceutical composition according to claim 1.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said administering comprises simultaneously or separately administering the inositol phosphorylceramide synthase inhibitor and amphotericin B or the salt thereof;
optionally, wherein the inositol phosphorylceramide synthase inhibitor comprises a cyclic depsipeptide antibiotic;
optionally, wherein the cyclic depsipeptide antibiotic comprises at least one of aureobasidin A, enniatin, destruxin, emodepside, or fusafungine;
optionally, wherein the cyclic depsipeptide antibiotic comprises aureobasidin A;
optionally, wherein the salt of amphotericin B, if present, comprises at least one of: sulfate, phosphate, citrate, tartrate, fumarate, benzoate, adipate, succinate, mesylate, or maleate of amphotericin B;
optionally, wherein the cyclic depsipeptide antibiotic and amphotericin B or the salt thereof are administered in combination at a mass ratio ranging from 1:3 to 5:1;
optionally, wherein the cyclic depsipeptide antibiotic and amphotericin B or the salt thereof are administered in combination d at a mass ratio ranging from 1:2 to 4:1;
optionally, wherein the cyclic depsipeptide antibiotic and amphotericin B or the salt thereof are administered in combination at a mass ratio of 1:2, 1:1, 2:1, or 4:1;
optionally, wherein the co-administration further comprises administering at least one of 5-fluorocytosine or an azole antifungal compound;
optionally, wherein the at least one of 5-fluorocytosine or the azole antifungal compound, the cyclic depsipeptide antibiotic, and amphotericin B or the salt thereof are administered simultaneously or separately;
optionally, wherein at least one of the at least one of 5-fluorocytosine or the azole antifungal compound, the cyclic depsipeptide antibiotic, or amphotericin B or the salt thereof is in a form of an injection preparation or an oral preparation.

### Claim 18 (depends on 1)

A method for treating or preventing a disease associated with Cryptococcus infection, comprising:
administering to a subject a pharmaceutically acceptable amount of the pharmaceutical composition according to claim 1;
optionally, wherein the disease associated with Cryptococcus infection comprises cryptococcal meningitis.
